Novo Nordisk A/S faces challenges in the obesity market, but new trials and innovations offer hope. Read more on NVO stock ...

Drugs that bind to and activate the receptors for the hormones GLP-1 and GIP are effective in the treatment of obesity and ...

She suggested I start taking the GLP-1 Zepbound through weekly injections, along with incorporating a healthy diet and ...

The likelihood for antibody-mediated rejection in lung transplant recipients was heightened with vs. without GLP-1 receptor ...

With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from ...

Meanwhile, Novo Nordisk struck deals with several telehealth companies to sell its GLP-1 drug semaglutide for obesity ...

There is a low incidence rate of suicide-related adverse events among adults with diabetes or obesity being treated with GLP-1 RAs.

Researchers at The University of Queensland have dosed 5 participants in the first clinical trial of a potentially ...

People taking GLP-1 receptor agonists appeared to be at elevated risk of rejection episodes after lung transplantation, a ...

GLP-1 use significantly lowered risk for atrial fibrillation-related events for patients with diabetes, AF and obesity, with ...

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.